Who is sponsoring NCT00414973?

NCT00414973 is sponsored by Eli Lilly and Company.

What condition does NCT00414973 study?

NCT00414973 studies Osteoporosis.

What drugs are being tested in NCT00414973?

Interventions: Teriparatide, Salmon Calcitonin.

What is the status of NCT00414973?

NCT00414973 is currently COMPLETED.

Last reviewed 2009-10-22 · How we verify

Comparison of Teriparatide and Calcitonin in the Treatment of Men and Postmenopausal Women With Osteoporosis

NCT00414973 Phase 3 COMPLETED Results posted

The purpose of this study is to compare the effect of injectable teriparatide to intranasal salmon calcitonin on lumbar spine bone mineral density, in the treatment of Chinese patients with established osteoporosis

Details

Lead sponsor	Eli Lilly and Company
Phase	Phase 3
Status	COMPLETED
Enrolment	364
Start date	2006-12
Completion	2008-07

Conditions

Osteoporosis

Interventions

Teriparatide
Salmon Calcitonin

Primary outcomes

Percentage Change From Baseline to 24 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD), Postmenopausal Women — Baseline to 24 weeks
Lumbar spine bone mineral density (milligrams per square centimeter) was measured by dual energy X-ray absorptiometry (DXA). Change = Endpoint minus baseline.

Countries

China